Healthcare / Diagnostics & ResearchASX
$2.00
-0.07 (-3.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $153.1M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$375M
P/E
14.3x
↓EV/EBITDA
3.5x
↓ROE
18.9%
↑Gross Margin
82.6%
↑Debt/Equity
1.69
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.4%
FCF CAGR
-12.8%
FCF margin
23.7%
FCF / Net income
5.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $736.1M · net income $32.4M · FCF $174.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $736.1M | $736.1M | $689.7M | $692.1M | $989.3M |
| Net Income | $32.4M | $32.4M | $23.9M | $35.9M | $178.2M |
| EBITDA | $188.0M | $188.0M | $169.7M | $174.6M | $362.3M |
| EPS | 0.17 | 0.17 | 0.12 | 0.18 | 0.88 |
| Gross Margin | 82.6% | 82.6% | 82.7% | 81.8% | 79.0% |
| Operating Margin | 8.5% | 8.5% | 8.1% | 7.5% | 27.1% |
| Net Margin | 4.4% | 4.4% | 3.5% | 5.2% | 18.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.69 | 1.69 | 1.74 | 1.83 | 1.13 |
| Current Ratio | 0.59 | 0.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $174.4M | $174.4M | $153.1M | $136.7M | $262.8M |
| Returns | |||||
| ROE | 18.9% | 18.9% | 13.5% | 20.8% | 76.7% |
| Valuation | |||||
| P/E | 14.29 | 14.29 | 21.08 | 18.77 | 5.09 |
| EV/EBITDA | 3.45 | 3.45 | 4.64 | 5.56 | 3.15 |
| P/B | 2.22 | 2.22 | 2.84 | 3.91 | 3.90 |
| Growth & Yield | |||||
| Revenue Growth | 6.7% | 6.7% | -0.3% | -30.0% | — |
| EPS Growth | 42.1% | 42.1% | -32.8% | -79.8% | — |
| Dividend Yield | 6.2% | 6.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1.3%
EPS terminal req.
$0.18
Spread vs growth
40.7%
5Y implied EPS CAGR
4.7%
EPS terminal req.
$0.21
Spread vs growth
37.4%
10Y implied EPS CAGR
7.3%
EPS terminal req.
$0.35
Spread vs growth
34.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.9%
Start / end P/E
23.2x → 11.7x
EPS bridge
0.12 → 0.17
Residual
-20.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.